Drugs / Meropenem-Vaborbactam
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VABOMERE | — | 2017-08-29 | fda.gov ↗ |
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02687906 | Jul 2016 → Dec 2026 expected | bacterial infectious disease | Melinta Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06672978 | Jun 2025 → Jan 2027 expected | acute pyelonephritis | Melinta Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02168946 | Jul 2014 → Jul 2017 | acute pyelonephritis, bacterial pneumonia, digestive system infectious disorder | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07004049 Comparator | Apr 2025 → Dec 2028 expected | bacterial pneumonia, infectious disease with sepsis | National University of Singapore | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | meropenem-vaborbactam | “Vabomere (meropenem-vaborbactam) for IV injection” NCT02687906 ↗ |
| Known as | Vabomere | “Vabomere (meropenem-vaborbactam) for IV injection” NCT02687906 ↗ |
| Route | Intravenous | “Vabomere, (meropenem-vaborbactam) administered as a fixed combination by intravenous (IV) infusion” NCT02168946 ↗ |